Abstract
Patients with cancer are at risk for many events involving the skeleton, including metastatic disease of bone and treatment-related bone loss. Cancer-related therapies that can affect bone include hormonal therapy, chemotherapy, and the use of glucocorticoids. Screening for bone loss, with lifestyle modifications and the early use of anti-osteoporosis therapies such as bisphosphonates, may decrease bone loss and reduce the risk of fracture. This article reviews risk factors and mechanisms associated with cancer-related bone loss and metastases as well as strategies for the detection of bone-related complications of cancer and therapies to treat these complications. This article focuses on the more common cancers with adverse skeletal effects: breast cancer, prostate cancer, and multiple myeloma.
Similar content being viewed by others
References and Recommended Reading
Kanis JA, Oden A, Johnell O, et al.: The components of excess mortality after hip fracture. Bone 2003, 32:468–473.
Oefelein MG, Ricchiuti V, Conrad W, et al.: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005–1007.
Roudier MP, Vesselle H, True LD, et al.: Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003, 20:171–180.
Coleman RE, Major P, Lipton A, et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925–4935.
Guise TA, Mohammad KS, Clines G, et al.: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s–6216s.
Roodman GD: Mechanisms of bone metastasis [review]. N Engl J Med 2004, 350:1655–1664.
Clines GA, Mohammad KS, Bao Y, et al.: Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007, 21:486–498.
Tian E, Zhan F, Walker R, et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483–2494.
Padalecki SS, Carreon MR, Grubbs B, et al.: Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid [abstract]. J Bone Miner Res 2002, 17:S310.
Lein M, Wirth M, Miller K, et al.: Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007, In press.
Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570–1593.
Hirbe A, Morgan EA, Uluckan O, Weilbaecher K: Skeletal complications of breast cancer therapies [review]. Clin Cancer Res 2006, 12:6309s–6314s.
Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005, 165:552–558.
Kanis JA, McCloskey EV, Powles T, et al.: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179–1181.
Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78–84.
Sverrisdottir A, Fornander T, Jacobsson H, et al.: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004, 22:3694–3699.
Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005, 365:60–62.
Perez EA, Josse RG, Pritchard KI, et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629–3635.
Coates AS, Keshaviah A, Thurlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486–492.
Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119–127.
Eastell R, Hannon RA, Cuzick J, et al.: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215–1223.
Gonnelli S, Cadirni A, Caffarelli C, et al.: Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007, 40:205–210.
Smith MR: Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2005, 2:608–615.
Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948–955.
Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.
Maillefert JF, Sibilia J, Michel F, et al.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161:1219–1222.
Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238–2245.
Morote J, Morin JP, Orsola A, et al.: Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007, 69:500–504.
Smith MR, Boyce SP, Moyneur E, et al.: Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006, 175:136–139; discussion 139.
Smith MR, Lee WC, Brandman J, et al.: Gonadotropin-releasing hormone agonists and fracture risk: a claim-sbased cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897–7903.
Shahinian VB, Kuo YF, Freeman JL, et al.: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154–164.
Giuliani N, Rizzoli V, Roodman GD: Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992–3996.
Melton LJ 3rd, Kyle RA, Achenbach SJ, et al.: Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005, 20:487–493.
Nelson HD, Helfand M, Woolf SH, et al.: Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:529–541.
Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042–4057.
Theriault RL, Biermann JS, Brown E, et al.: NCCN Task Force report: bone health and cancer care. J Natl Compr Canc Netw 2006, 4(suppl 2):S1–S20.
Powles T, Paterson A, McCloskey E, et al.: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458–1468.
Rosen LS, Gordon D, Kaminski M, et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735–1744.
Diamond TH, Winters J, Smith A, et al.: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444–1450.
Ryan CW, Huo D, Demers LM, et al.: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006, 176:972–978.
Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038–1042.
Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829–836.
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820–828.
Greenspan SL, Nelson JB, Trump DL, et al.: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416–424.
Greenspan SL, Bhattacharya RK, Sereika SM, et al.: Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007, 92:131–136.
Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727–2741.
Guarneri V, Donati S, Nicolini M, et al.: Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005, 10:842–848.
Bamias A, Kastritis E, Bamia C, et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580–8587.
American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137:1144–1150.
Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753–761.
Shane E, Goldring S, Christakos S, et al.: Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006, 21:1503–1505.
Lacy MQ, Dispenzieri A, Gertz MA, et al.: Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006, 81:1047–1053.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, S.A., Guise, T.A. Cancer-associated bone disease. Curr Osteoporos Rep 5, 120–127 (2007). https://doi.org/10.1007/s11914-007-0027-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11914-007-0027-8